Citadel Advisors’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Citadel Advisors’s Portfolio KRBP Stock Details KRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,329	Closed	-$10.7K	–	15755
2022 Q3	$12K	Buy	1,329 +673	+103%	+$7.81K	﹤0.01%	12242
2022 Q2	$9K	Buy	656 +300	+84%	+$4.73K	﹤0.01%	12620
2022 Q1	$9K	Sell	356 -1,088	-75%	-$32.2K	﹤0.01%	13392
2021 Q4	$66K	Buy	1,444 +555	+62%	+$37.8K	﹤0.01%	13087
2021 Q3	$82K	Buy	+889	New	+$92K	﹤0.01%	13058
2021 Q2	–	Sell	-724	Closed	-$203K	–	14725
2021 Q1	$203K	Buy	724 +336	+87%	+$98.5K	﹤0.01%	11676
2020 Q4	$97K	Buy	+388	New	+$110K	﹤0.01%	10243

Other funds holding KRBP

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's KRBP Position: Q4 2022 in Review

Citadel Advisors sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q4 2022, closing a stake of 1,329 shares — an estimated $10.7K sold.

Citadel Advisors first reported a position in KRBP in Q4 2020 and held it in 7 quarters. The position peaked at $203K in Q1 2021. 12 funds tracked by Wall St. Rank hold KRBP as of Q4 2022.

Citadel Advisors reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Citadel Advisors sold 1,329 Kiromic BioPharma, Inc. Common Stock shares in Q4 2022, an estimated $10.7K.
Citadel Advisors first reported a position in Kiromic BioPharma, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
Citadel Advisors's Kiromic BioPharma, Inc. Common Stock position peaked at $203K in Q1 2021.
12 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.